Life AI Net
Start
Archiv
Rechner
Verzeichnis
Newsletter
Hot
Anmelden
Deutsch
English
简体中文
Deutsch
Français
Español
日本語
한국어
العربية
Auto
Start
Archiv
Rechner
Verzeichnis
Newsletter
English
简体中文
Deutsch
Français
Español
日本語
한국어
العربية
Auto
Anmelden
Start
Archiv
Rechner
Verzeichnis
More
Live
FierceBiotech
Foundation Medicine expands Bristol Myers Squibb collaboration with new diagnostic target
FierceBiotech
In a Merck Litespark shocker, Welireg triplet misses the mark in first-line kidney cancer
FierceBiotech
Ray Therapeutics shines a light on $125M round targeting genetic eye therapy
FierceBiotech
Tortugas comes out of its shell with $106M to fund 4 phase 2-stage neuro drugs licensed from Asia
FierceBiotech
Pfizer's strategy head Andrew Baum to step down following brief tenure: reports
Lonza News
Simulations Plus (SLP) Partners with FDA and Lonza for Drug Perf - GuruFocus
Lonza News
Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks fo - PharmiWeb.com
Lonza News
Simulations Plus partners with Lonza and FDA on drug formulation research - Investing.com
BioWorld
Japanese researchers report new μ-opioid receptor antagonists
BioWorld
Incyte discloses new TYK2 and/or JAK1 inhibitors
BioWorld
Insilico Medicine divulges new NLRP3 inflammasome inhibitors
BioWorld
Neolaia synthesizes new CD38 inhibitors
FierceBiotech
Foundation Medicine expands Bristol Myers Squibb collaboration with new diagnostic target
FierceBiotech
In a Merck Litespark shocker, Welireg triplet misses the mark in first-line kidney cancer
FierceBiotech
Ray Therapeutics shines a light on $125M round targeting genetic eye therapy
FierceBiotech
Tortugas comes out of its shell with $106M to fund 4 phase 2-stage neuro drugs licensed from Asia
FierceBiotech
Pfizer's strategy head Andrew Baum to step down following brief tenure: reports
Lonza News
Simulations Plus (SLP) Partners with FDA and Lonza for Drug Perf - GuruFocus
Lonza News
Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks fo - PharmiWeb.com
Lonza News
Simulations Plus partners with Lonza and FDA on drug formulation research - Investing.com
BioWorld
Japanese researchers report new μ-opioid receptor antagonists
BioWorld
Incyte discloses new TYK2 and/or JAK1 inhibitors
BioWorld
Insilico Medicine divulges new NLRP3 inflammasome inhibitors
BioWorld
Neolaia synthesizes new CD38 inhibitors
Archiv
Suchen
Suchen
Aktuell
Älteste
Löschen
@BioWorld
Gesamt
1057
Quelle
BioWorld
Suche
--
BioWorld
27. März 2026
Chengdu Sibeibo divulges new PARP-14 inhibitors
BioWorld
27. März 2026
Pinnacle raises an $89M series B for its oral peptide programs
BioWorld
26. März 2026
Financings for March 26, 2026
BioWorld
26. März 2026
In the clinic for March 26, 2026
BioWorld
26. März 2026
Other news to note for March 26, 2026
BioWorld
26. März 2026
Regulatory actions for March 26, 2026
BioWorld
26. März 2026
Corvus leads drug developers as index climbs in early 2026
BioWorld
26. März 2026
Kodiak’s Zenkuda sparkles in Glow2, BLA filing next
BioWorld
26. März 2026
Atai Therapeutics patents new 5-HT2 receptor agonists
BioWorld
26. März 2026
Bolt Biotherapeutics discloses new STING agonist immunoconjugates
BioWorld
26. März 2026
The Scripps Research Institute identifies new DNA topoisomerase inhibitors
BioWorld
26. März 2026
Ensem Therapeutics synthesizes new WRN inhibitors
BioWorld
26. März 2026
NLRP3 inflammasome inhibitors reported in Uppthera patent
BioWorld
25. März 2026
Financings for March 25, 2026
BioWorld
25. März 2026
In the clinic for March 25, 2026
BioWorld
25. März 2026
Other news to note for March 25, 2026
BioWorld
25. März 2026
Regulatory actions for March 25, 2026
BioWorld
25. März 2026
Corcept’s Lifyorli wins early FDA approval for ovarian cancer
Zurück
10 / 59
Weiter